Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print SYNTAX defines borders between CABG and PCI with TAXUS drug-eluting stents

SYNTAX defines borders between CABG and PCI with TAXUS drug-eluting stents

February 23, 2009

Coronary artery bypass grafting (CABG) should remain the "standard of care" for patients with complex coronary artery disease, concludes the SYNTAX study, published in the New England Journal of Medicine (online February 18, 2009, Print edition March 5).

The SYNTAX study, led jointly by Patrick Serruys from Erasmus University Medical Center (Rotterdam, the Netherlands) and Fred Mohr from the University of Leipzig (Germany), set out to compare CABG and PCI using DES to investigate whether the situation has changed. The findings of the SYNTAX study were first presented at the European Society of Cardiology meeting in Munich, August 30 to September 3, 2008.




Improved technology is making it possible to treat increasingly complex coronary artery lesions with percutaneous coronary intervention (PCI), a technique first introduced in 1977. But studies comparing PCI using bare metal stents (BMS) with CABG - such as the ARTS I, SoS and MASS II studies - showed that higher rates of repeat revascularization procedures were needed following PCI. Set against this background, other studies have been showing that newer drug eluting stents (DES) require less repeat revascularization than the older BMS.

Commenting on the study, Dr William Wijns, spokesperson for the European Society of Cardiology and president of the European Association for Percutaneous Cardiovascular Interventions (EAPCI) said: "The SYNTAX study shows the importance of including both interventional cardiologists and cardiac surgeons in the decision making process. The fact SYNTAX concludes CABG should be considered the standard of care means all centres should be standing back and considering it."

But before drawing any firm conclusions from the SYNTAX data, he cautioned, it is important to wait for the two year update, expected to be presented at the European Society of Cardiology annual meeting in September 2009. "The big caveat with SYNTAX is that with CABG the highest risk of problems occurs in the first month following surgery, but with PCI problems gradually increase with time. It's therefore possible that the two year data will show the curves diverging."

Commenting on the SYNTAX score data for PCI, Dr Wijns said that wider use of the scoring system would provide clarity on which patients were most appropriate for different procedure. "Until now the borders between PCI and CABG have been quite blurred, but these results show that PCI can give excellent results in a predefined lower to intermediate risk sub group, but that it's not appropriate for high risk groups," he said, adding that he looked forward to the score becoming widely available so that clinicians could use it in the decision making process.

The European Society of Cardiology has recently set up a new joint task force with the European Association for Cardio Thoracic Surgery to produce guidelines on revascularization procedures. "Previously we had guidelines looking at PCI, but this time we plan to have guidelines reviewing the clinical issue of choosing the best revascularisation procedure for different patients," said Dr Wijns. The American College of Cardiology Foundation , Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgery have recently published guidelines (online JACC, Jan 5 2009) reviewing appropriate revascularization procedures in 180 different clinical scenarios. These guidelines, however, were prepared prior to the availability of SYNTAX results.

Between March 2005 and April 2007, 1800 patients with three-vessel or left main coronary artery disease (considered the most complex cases), from 62 sites in Europe and 23 sites in North America, were randomly assigned to undergo CABG or PCI in a 1:1 ratio. Patients were only entered into the randomisation if an interventional cardiologist and cardiac surgeon both judged that they could achieve equivalent results with either procedure. Patients for whom only one treatment option was considered suitable were entered into either a PCI registry (n=198) or a CABG registry (n=1,077), with data reported separately.

Results at 12 months show that the rates of major adverse cardiac or cerebrovascular events (defined as the primary end point for the study) were significantly higher in the PCI group than the CABG group (17.8 % versus 12.4%, P=0.002). The differences could be largely accounted for by patients in the PCI group requiring increased repeat revascularization. Altogether 13.5 % of patients in the PCI group underwent repeat revascularization compared to 5.9 % in the CABG group (P<0.001).

At 12 months the rates of overall death (defined as the secondary end point) were similar for the two groups - 3.5 % in the CABG group versus 4.4% in the PCI group ( P=0.37). Stroke, however, was significantly more likely to occur in the CABG population - 2.2 % of CABG patients experienced stroke compared with 0.6 % of PCI patients (P=0.003).

For the first time investigators used a measure known as the SYNTAX score, which had been designed to evaluate the complexity of the coronary disease. By splitting the population in tertiles, a low score was defined as less than 22, an intermediate score as between 23 and 32 and a high score as greater than 33. For patients receiving CABG, the major adverse cardiac or cerebrovascular events were similar in all three SYNTAX score groups. In contrast, for patients receiving PCI, the rate of major adverse cardiac or cerebrovascular events was 23.4 % for those with high SYNTAX scores, 16.7 % for those with intermediate scores and 13.6 % for those with low scores. For high versus low scores P=0.002.

In an accompanying editorial Richard Lange and David Hillis, from the University of Texas Health Science Center in San Antonio, considered the increased risk of stroke in CABG patients. "The investigators do not discuss whether the strokes were related to the procedure or whether the risk of having a stroke was influenced by differences between the two groups in the occurrence of atrial fibrillation, use of aspirin or other antiplatelet agents, or presence of risk factors for atherosclerosis*," they write.

European Society of Cardiology



Related Drug-eluting Stents Current Events and Drug-eluting Stents News Articles Drug-eluting Stents Current Events and Drug-eluting Stents News RSS Drug-eluting Stents Current Events and Drug-eluting Stents News RSS
Higher carotid arterial stenting rates associated with poorer clinical outcomes
Among eligible Medicare beneficiaries, increased use of carotid arterial stenting (CAS) procedures to treat carotid stenosis-the narrowing of the carotid artery-is associated with higher rates of mortality and adverse clinical outcomes, including heart attack and stroke, according to researchers from the University of Pennsylvania School of Medicine.

Drug-eluting stents better than bare-metal stents for heart attack patients
Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.

SPIRIT IV trial shows everolimus stent sets new standard for event-free survival
Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety.

Drug-eluting stents safe, effective for treatment of chronic total occlusions
A multicenter study in Asia found drug-eluting stents effective with a low rate of acute complications in patients with chronic total occlusions (CTOs) undergoing PCI. Results of the study will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

Researchers find drug-eluting stents safe, effective for PCI in diabetics
Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

Fast release of data leads to rapid changes in clinical practice for drug-eluting stents
E-mail, search engines, smart phones and other new technologies that can disseminate new medical information quickly led to an almost immediate change in clinical practice for drug-eluting stents, according to a study reported in Circulation: Cardiovascular Quality and Outcomes.

Analysis of drug-eluting stents data demonstrates safety, efficacy in on-and-off-label use
The Cardiovascular Research Foundation (CRF) announced that results of the largest meta-analysis to date comparing mortality rates for drug-eluting stents (DES) versus bare metal stents (BMS) were published online June 15 in the journal Circulation.

NEJM study finds drug-eluting stents more effective than bare-metal stents in heart attack patients
NewYork-Presbyterian Hospital and Columbia University Medical Center, together with the Cardiovascular Research Foundation (CRF), announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published in the May 7 New England Journal of Medicine.

Drug-eluting stents prove more effective, equally as safe as bare-metal stents
The Cardiovascular Research Foundation (CRF) announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published today in The New England Journal of Medicine.

Drug-eluting stents found safe, superior to bare metal stents
Drug-eluting stents were safe and superior to bare metal stents in preventing death and heart attacks among 262,700 "real-world" patients enrolled in a nationwide registry of cardiovascular disease, according to researchers from Duke University Medical Center.
More Drug-eluting Stents Current Events and Drug-eluting Stents News Articles
Handbook of Drug-Eluting Stents

Handbook of Drug-Eluting Stents
by Patrick W. Serruys (Author), Anthony H. Gershlick (Author)

Over the past few years, the focus in interventional cardiology research has centered on reducing restenosis with the use of antiproliferative pharmacological agents. The use of these drugs, hitherto, has failed, most probably because of low active drug levels at the target site. This problem led to the development of local drug delivery using stents, since they can serve as a reservoir for local drug administration and are in immediate contract with the coronary artery wall, thus ensuring maximum delivery of the pharmacological agent. Drug-eluting stents provide an entirely new spectrum of potential therapies for restenosis. Handbook of Drug-Eluting Stents, under the editorial direction of Patrick Serruys, one of the world's leading interventional cardiologists, and Tony Gershlick, a...

Drug-eluting Stents: Are they Safe?

Drug-eluting Stents: Are they Safe?

Drug-eluting stents are metal mesh tubes coated with medication that keep arteries from re-blocking after angioplasty. These devices have been the solution for millions of people around the world. However, recent studies have raised concerns about associated risks. Join Dr. Yeung and colleagues as they discuss the safety of these popular devices

This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply.

  The 2009-2014 Outlook for Drug-Eluting Stents in Europe
by Icon Group International (Author)

This econometric study covers the outlook for drug-eluting stents in Europe. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-a-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is...

Colombo's Tips & Tricks for Drug Eluting Stents

Colombo's Tips & Tricks for Drug Eluting Stents
by Antonio Colombo (Author), Goran Stankovic (Author)

A trailblazer in interventional cardiology, Dr. Antonio Colombo combines his vast experience with that of Goran Stankovic and distinguished colleagues to share tips and tricks for dealing with diseased coronary arteries. Whether discussing his 'crushing and kissing' techniques or the stenting of tortuous vessels in the elderly, Dr. Colombo and his colleagues' texts and case commentaries provide the reader with succinct and simple advice based on personal experience. They provide the most comprehensive and practical guide available for those involved in coronary artery stenting. The images are all down-loadable in Powerpoint and will be of tremendous use to instructors and students alike.

  IMPROVED JANUS FLEX DRUG ELUTING STENT LAUNCHED IN EUROPE.: An article from: Biotech Equipment Update
by Thomson Gale (Publisher)

This digital document is an article from Biotech Equipment Update, published by Thomson Gale on April 1, 2006. The length of the article is 498 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: IMPROVED JANUS FLEX DRUG ELUTING STENT LAUNCHED IN EUROPE.
Publication: Biotech Equipment Update (Newsletter)
Date: April 1, 2006
Publisher: Thomson Gale
Volume: 14 Issue: 4 Page: NA

Distributed by Thomson Gale

  MEDIVAS/ESTRACURE SIGN PACT FOR DRUG ELUTING STENT.: An article from: Biotech Equipment Update
by Worldwide Videotex (Publisher)

This digital document is an article from Biotech Equipment Update, published by Worldwide Videotex on September 1, 2005. The length of the article is 488 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: MEDIVAS/ESTRACURE SIGN PACT FOR DRUG ELUTING STENT.
Publication: Biotech Equipment Update (Newsletter)
Date: September 1, 2005
Publisher: Worldwide Videotex
Volume: 13 Issue: 9 Page: NA

Distributed by Thomson Gale

  Up to six drug-eluting stents to hit U.S. market: the new models are expected to improve deliverability and increase competition, which might reduce costs.: An article from: Internal Medicine News
by Mitchel L. Zoler (Author)

This digital document is an article from Internal Medicine News, published by Thomson Gale on March 15, 2006. The length of the article is 1035 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Up to six drug-eluting stents to hit U.S. market: the new models are expected to improve deliverability and increase competition, which might reduce costs.
Author: Mitchel L. Zoler
Publication: Internal Medicine News (Magazine/Journal)
Date: March 15, 2006
Publisher: Thomson Gale
Volume: 39 Issue: 6 Page: 57(1)

Distributed by Thomson...

  Pro & Con: is it too early to jump on the bandwagon for drug-eluting stents?: An article from: Family Practice News
by International Medical News Group (Publisher)

This digital document is an article from Family Practice News, published by International Medical News Group on December 1, 2002. The length of the article is 885 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Pro & Con: is it too early to jump on the bandwagon for drug-eluting stents?
Publication: Family Practice News (Magazine/Journal)
Date: December 1, 2002
Publisher: International Medical News Group
Volume: 32 Issue: 23 Page: 10(1)

Distributed by Thomson...

Drug Eluting Stents: Anti-Inflammatory Approach To Prevent Restenosis After Stent Implantation (Acta Biomedica Lovaniensia)

Drug Eluting Stents: Anti-Inflammatory Approach To Prevent Restenosis After Stent Implantation (Acta Biomedica Lovaniensia)
by Yanming Huang (Author)



  Is it too early to jump on the bandwagon for drug-eluting stents? (Pro & Con).: An article from: Internal Medicine News
by International Medical News Group (Publisher)

This digital document is an article from Internal Medicine News, published by International Medical News Group on December 1, 2002. The length of the article is 856 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Is it too early to jump on the bandwagon for drug-eluting stents? (Pro & Con).
Publication: Internal Medicine News (Magazine/Journal)
Date: December 1, 2002
Publisher: International Medical News Group
Volume: 35 Issue: 23 Page: 10(1)

Distributed by Thomson...

© 2009 BrightSurf.com